Abbott Labs (ABT) Stock Falls on Baby Formula Ruling. What to Know.

Abbott Labs (NYSE:ABT) stock is falling more than 4% after a St. Louis jury found its premature infant baby formula responsible for a potentially fatal bowel disease.As of this writing, ABT stock is trading around the $100 mark. The market capitalization of Abbott is $175 billion on estimated sales of $38.4 billion for 2024. A Formula for Legal TroubleThe case was filed on behalf of Margo Gill and her daughter, who developed necrotizing enterocolitis (NEC) and suffered severe brain damage after being given ...